Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.45 |
| ▸ | TK2 | O00142 | 5/20 | 0.42 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.40 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.40 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.40 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.40 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.40 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.40 |
| ▸ | TK1 | P04183 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15798320 | 1.00 | PYGM (0.45) | PYGMTK2SLC5A2P2RY2SLC28A1 | |
| SCHEMBL18852463 | 1.00 | PYGM (0.45) | PYGMTK2SLC5A2P2RY2SLC28A1 | |
| SCHEMBL17210979 | 1.00 | PYGM (0.45) | PYGMTK2SLC5A2P2RY2SLC28A1 | |
| SCHEMBL15810644 | 1.00 | PYGM (0.45) | PYGMTK2SLC5A2P2RY2SLC28A1 | |
| SCHEMBL17210982 | 0.90 | PYGM (0.44) | PYGMTK2SLC5A2P2RY2SLC28A1 | |
| SCHEMBL15798586 | 0.90 | PYGM (0.44) | PYGMTK2SLC5A2P2RY2SLC28A1 | |
| SCHEMBL15810682 | 0.90 | PYGM (0.44) | PYGMTK2SLC5A2P2RY2SLC28A1 | |
| SCHEMBL19007490 | 0.90 | PYGM (0.44) | PYGMTK2SLC5A2P2RY2SLC28A1 | |
| SCHEMBL18870659 | 0.90 | PYGM (0.44) | PYGMTK2SLC5A2P2RY2SLC28A1 | |
| SCHEMBL15798509 | 0.90 | PYGM (0.47) | PYGMTK2SLC5A2P2RY2SLC28A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190255194-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX INC (US) | 2019-08-22 | — | — | US | disclosed |
| EP-2931319-B1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX INC (US) | 2019-08-21 | — | — | EP | disclosed |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190255194-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | PYGM 2038/4885TK2 305/4885SLC5A2 2966/4885 |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | PYGM 2038/4885TK2 305/4885SLC5A2 2966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.